Implications for Practice
tumors, TNBCs
TUMORS
Ipatasertib is a selective pan-AKT inhibitor and displays synergy with chemotherapy preclinically. This study was designed to determine the dose, safety, and preliminary efficacy of ipatasertib plus carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in mTNBC. The combination was safe and well-tolerated at the recommended doses, with empirically higher efficacy seen in tumors harboring PIK3CA/AKT/PTEN alterations. In addition, androgen receptor-positivity was associated with an empirically higher response rate. This study was stopped early due to a Phase III study combining ipatasertib plus paclitaxel that failed to show PFS or OS benefit. Further analysis is warranted in understanding the role of AKT inhibition in the treatment of TNBCs.